ClinicalTrials.gg
CompletedNCT02938481T-REXUpdated Jan 29, 2026

International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer

An observational study in Colon Cancer, sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan. Completed at 36 sites in 7 countries. Per ClinicalTrials.gov, last updated 2026-01-29.

Sponsored by Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
3,647
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 37 studies in Colonic Neoplasms with a site in Japan — 9 open to participants now, 16 under way, 5 of them phase 3. Colonic Neoplasms · Japan.

Started
2013
with 1 other
Observational
7 of 37
2 open now
Registered
17th of 37
by date
Lead sponsor
5 of 37
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan

Among the 37 studies in Colonic Neoplasms with a site in Japan, this one is one of 2 that started in 2013, is one of 7 observational ones, and was the 17th registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 457 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

9 of the 37 studies in Colonic Neoplasms with a site in Japan are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 327 Colonic Neoplasms studies recruiting now, 203 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Colonic Neoplasms with a site in Japan, or all of them as a file.
02

Study summary

The T-REX study aims to clarify the actual status of metastatic lymph node (LN) distribution in colon cancer and provide reliable evidence regarding the optimal length of bowel resection and the extent of central lymph node dissection in colon cancer surgery.

Read the detailed description

In colon canser, the incidence of metastasis in the pericolic lymph nodes (LNs) located along the bowel and marginal artery is high. The optimal extent of bowel resection is closely associated with how we define 'regional' pericolic LNs, which should be resected because of the risk of metastasis. However, there are no standardised criteria for 'regional' LNs in the pericolic area.

To establish a consensus for the extent of bowel resection and appropriate central LN dissection, international prospective stdies focusing on the distribution of metastatic LNs along the bowel and the primary feeding artery are conducted.

03

Conditions studied

  • Colon Cancer

Browse trials for

Keywords

  • colon cancer, lymph node, extent of bowel resection
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with colon cancer who will receive potentially curative surgery at participating institutions between 22 Jan 2015 and 22 Jan 2020.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven colon adenocarcinoma
  • Pathological stage Ⅰ, Ⅱ or Ⅲ
  • Potentially curative surgery
  • for observational data collection

Exclusion criteria

Exclusion Criteria:

  • Tis (mucosal cancer)
  • Multiple colon cancers
  • All patients with preoperative therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
3,647 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Distribution of metastatic LNs

    Time frame: At the time of patient registry in

  2. Distribution of metastatic LNs

    Time frame: At the time of 4 years after surgery

Secondary outcomes

  1. Prognostic outcomes according to the length of bowel resection

    Time frame: 4 years

  2. Prognostic outcomes according to the central radicality

    Time frame: 4 years

07

Study locations

36 sites
  • University Hospital Erlangen
    Erlangen, Bavaria 91054, Germany
  • Aichi Cancer Centre Hospital
    Nagoya, Aichi-ken 464-8681, Japan
  • Fujita Health University
    Toyoake, Aichi-ken 470-1192, Japan
  • National Canser Centre Hospital East
    Chiba, Chiba 277-8577, Japan
  • Teikyo University Chiba Medical Center
    Ichihara-shi, Chiba, Japan
  • Keiyukai Sapporo Hospital
    Sapporo, Hokkaido 003-0027, Japan
  • Kurume University School of Medicine
    Kurume, Hukuoka-prefecture 830-0011, Japan
  • Yokohama City University Medical Center
    Yokohama, Kanagawa 232-0024, Japan
  • Saisei-kai Yokohama-shi Nanbu Hospital
    Yokohama, Kanagawa 234-0054, Japan
  • Yokohama-city University
    Yokohama, Kanagawa 236-0004, Japan
  • Kanagawa Cancer Centre Hospital
    Yokohama, Kanagawa 241-8515, Japan
  • Takano Hospital
    Kumamoto, Kumamoto 862-0924, Japan
  • Mie University Graduate School of Medicine
    Tsu, Mie-ken 514-8507, Japan
  • Niigata Cancer Center Hospital
    Niigata, Niigata, Japan
  • Osaka International Cancer Institute
    Osaka, Osaka 537-8511, Japan
  • Saitama Cancer Center
    Kitaadachi-gun, Saitama 362-0806, Japan
  • National Defense Medical College
    Tokorozawa, Saitama 359-8513, Japan
  • Shiga University of Medical Science
    Ōtsu, Shiga, Japan
  • Shizuoka Cancer Centre Hospital
    Sunto-gun, Shizuoka 411-8777, Japan
  • Tochigi Cancer Center
    Utsunomiya, Tochigi, Japan
  • Tokyo Medical and Dental University
    Bunkyo-ku, Tokyo 113-8519, Japan
  • Tokyo Metropolitan Cancer and Infectious Disease Centre Komagome Hospital
    Bunkyo-ku, Tokyo 113-8677, Japan
  • National Cancer Centre Central Hospital
    Chuo-ku, Tokyo 104-0045, Japan
  • Teikyo University School of Medicine
    Itabashi-ku, Tokyo 173-8605, Japan
  • Kyorin University School of Medicine
    Mitaka, Tokyo 181-8611, Japan
  • Tokyo Women's Medical University
    Shinjuku-ku, Tokyo 162-8666, Japan
  • Wakayama Medical University
    Wakayama, Wakayama, Japan
  • Yamagata Prefectural Central Hospital
    Yamagata, Yamagata 990-2292, Japan
  • Klaipeda University hospital
    Klaipėda, Lietuva, Lithuania
  • National Cancer Institute, Lithuania
    Vilnius, Lithuania
  • I.M. Sechenov First Moscow State Medical University
    Moscow, Russia
  • Yonsei University
    Seodaemun-gu, Seoul 03722, South Korea
  • University of Ulsan College of Medicine and Asan Medical Center
    Songpa-Gu, Seoul, South Korea
  • China Medical University Hospital
    Taichung, 40447, Taiwan
  • National Taiwan University Hospital
    Taipei, Taiwan
  • University of Leeds
    Leeds, West Yorkshire LS2 9JT, United Kingdom
08

References and documents

Publications

  • Shiozawa M, Ueno H, Shiomi A, Kim NK, Kim JC, Tsarkov P, Grutzmann R, Dulskas A, Liang JT, Samalavicius N, West N, Sugihara K. Study protocol for an International Prospective Observational Cohort Study for Optimal Bowel Resection Extent and Central Radicality for Colon Cancer (T-REX study). Jpn J Clin Oncol. 2021 Jan 1;51(1):145-155. doi: 10.1093/jjco/hyaa115. PubMed 33215206 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2013 to primary completion in Dec 2023, 127 months.

Of 186 non-industry observational studies under Colonic Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 116. This study's 127 months is above that.

Counting every sponsor, half of 225 studies reached it within 50 months; a quarter within 27 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2016
First posted
Oct 19, 2016
StartActual
May 30, 2013
Primary completionActual
Dec 31, 2023
CompletionActual
Jan 31, 2025
Last update
Jan 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02938481
Lead sponsor
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Collaborators
Tokyo Medical and Dental University, Japan
Responsible party
Sponsor
First posted
Oct 19, 2016
Start date
May 30, 2013
Primary completion
Dec 31, 2023
Completion
Jan 31, 2025
Last update
Jan 29, 2026

Study contacts

Kenichi Sugihara, M.D., Ph.D
study director · Tokyo Medical and Dental University, Japan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion